Olympiad Research LP Purchases 15,924 Shares of Catalent, Inc. (NYSE:CTLT)

Olympiad Research LP boosted its position in Catalent, Inc. (NYSE:CTLT) by 93.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,009 shares of the company’s stock after buying an additional 15,924 shares during the period. Catalent makes up approximately 1.3% of Olympiad Research LP’s portfolio, making the stock its 13th biggest position. Olympiad Research LP’s holdings in Catalent were worth $1,999,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CTLT. Mirae Asset Global Investments Co. Ltd. increased its position in Catalent by 33.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock valued at $1,230,000 after buying an additional 5,499 shares in the last quarter. BNP Paribas Financial Markets increased its position in Catalent by 154.6% in the 1st quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock valued at $12,211,000 after buying an additional 131,360 shares in the last quarter. Nordea Investment Management AB increased its position in Catalent by 10.2% in the 1st quarter. Nordea Investment Management AB now owns 11,874 shares of the company’s stock valued at $672,000 after buying an additional 1,096 shares in the last quarter. Daiwa Securities Group Inc. increased its position in Catalent by 8.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company’s stock valued at $1,490,000 after buying an additional 2,017 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Catalent in the 1st quarter valued at about $625,000.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.31% of the company’s stock.

Catalent Price Performance

Shares of NYSE CTLT opened at $59.95 on Thursday. Catalent, Inc. has a twelve month low of $32.38 and a twelve month high of $61.20. The stock’s 50 day moving average price is $60.03 and its 200-day moving average price is $58.03. The company has a market capitalization of $10.88 billion, a PE ratio of -10.92, a PEG ratio of 2.06 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the firm earned ($0.10) EPS. Catalent’s quarterly revenue was up 4.2% on a year-over-year basis. On average, equities analysts anticipate that Catalent, Inc. will post 0.95 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.